CBT-004
/ Cloudbreak Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 05, 2025
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
(clinicaltrials.gov)
- P2 | N=88 | Completed | Sponsor: Cloudbreak Therapeutics, LLC | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ May 2025 | Trial primary completion date: Aug 2025 ➔ Apr 2025
Trial completion • Trial completion date • Trial primary completion date • Ophthalmology
January 29, 2024
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
(clinicaltrials.gov)
- P2 | N=75 | Recruiting | Sponsor: Cloudbreak Therapeutics, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ Oct 2025 | Trial primary completion date: Dec 2023 ➔ Aug 2025
Enrollment open • Trial completion date • Trial primary completion date • Ophthalmology
January 27, 2023
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
(clinicaltrials.gov)
- P2 | N=75 | Not yet recruiting | Sponsor: Cloudbreak Therapeutics, LLC | Trial primary completion date: Sep 2023 ➔ Dec 2023
Trial primary completion date • Ophthalmology
April 29, 2022
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
(clinicaltrials.gov)
- P2 | N=75 | Not yet recruiting | Sponsor: Cloudbreak Therapeutics, LLC | Trial completion date: Dec 2022 ➔ Dec 2023 | Initiation date: Mar 2022 ➔ Nov 2022 | Trial primary completion date: Sep 2022 ➔ Sep 2023
Trial completion date • Trial initiation date • Trial primary completion date • Ophthalmology
1 to 4
Of
4
Go to page
1